Oncology News | pharmaphorum

News

Cancer biotech Nouscom adds €120m, and other financings

A €120m Series D for Swiss biotech Nouscom will support trials of a Lynch syndrome vaccine, with Soufflé, Estuary, and Microbiotica also raising cash.

News

RevMed nears EU okay for pancreatic cancer drug Rasonque

Revolution Medicines is just weeks away from getting EU approval for its keenly anticipated oral RAS drug Rasonque for pancreatic cancer.

News

ImmunityBio bags elusive label extension for Anktiva

The FDA has handed ImmunityBio a key label extension for bladder cancer therapy Anktiva, giving it a leg-up on rival drug Inlexzo from J&J.

News

Roche breast cancer drug Itovebi turned down by NICE

NICE turns down NHS use of Roche's breast cancer drug Itovebi, which the company says reveals a flaw in the appraisal of combination therapies.

News

BioNTech sticks with cancer vaccine despite trial miss

BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.

News

Iambic prices its IPO, seeking to raise up to $160m

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

Cancer biotech Nouscom adds €120m, and other financings

RevMed nears EU okay for pancreatic cancer drug Rasonque

ImmunityBio bags elusive label extension for Anktiva

Roche breast cancer drug Itovebi turned down by NICE

BioNTech sticks with cancer vaccine despite trial miss

Iambic prices its IPO, seeking to raise up to $160m

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks